Muscle diseases: The muscular dystrophies

Annual Review of Pathology

Volumn 2, Issue , 2007, Pages 87-109

  McNally, Elizabeth M ^a   Pytel, Peter ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Dystrophin; Lamin A C; Muscle regeneration; Myotonia; Nucleotide repeat expansion; Sarcopenia

Indexed keywords

CALPAIN; CAVEOLIN; CONNECTIN; DYSFERLIN; SARCOGLYCAN; SOMATOMEDIN;

CELL MEMBRANE; EXTRACELLULAR MATRIX; GENETIC ASSOCIATION; HUMAN; MUSCLE ATROPHY; MUSCLE DISEASE; MUSCLE REGENERATION; MUSCULAR DYSTROPHY; MYOPATHY; MYOTONIC DYSTROPHY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 33947377423     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.2.010506.091936     Document Type: Review

References (113)

1. Mauro A. 1961. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 9:493-95
2. Relaix F, Rocancourt D, Mansouri A, Buckingham M. 2005. A Pax3/Pax7-dependent population of skeletal muscle progenitor cells. Nature 435:948-53
3. LaBarge MA, Blau HM. 2002. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 111:589-601
4. Morgan JE, Partridge TA. 2003. Muscle satellite cells. Int. J. Biochem. Cell Biol. 35:1151-56
5. Kobayashi K, Nakahori Y, Miyake M, Matsumura K, Kondo-Iida E, et al. 1998. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 394:388-92
6. Yoshida A, Kobayashi K, Manya H, Taniguchi K, Kano H, et al. 2001. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 1:717-24
7. Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, Celli J, van Beusekom E, et al. 2002. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am. J. Hum. Genet. 71:1033-43
8. Beltran-Valero de Bernabe D, Voit T, Longman C, Steinbrecher A, Straub V, et al. 2004. Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J. Med. Genet. 41:e61
9. Mercuri E, Brockington M, Straub V, Quijano-Roy S, Yuva Y, et al. 2003. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann. Neurol. 53:537-42
10. Barresi R, Campbell KP. 2006. Dystroglycan: from biosynthesis to pathogenesis of human disease. J. Cell Sci. 119:199-207
11. Brancaccio A. 2005. Alpha-dystroglycan, the usual suspect? Neuromuscul. Disord. 15:825-28
12. Durbeej M, Henry MD, Campbell KP. 1998. Dystroglycan in development and disease. Curr. Opin. Cell Biol. 10:594-601
13. Gee SH, Blacher RW, Douville PJ, Provost PR, Yurchenco PD, Carbonetto S. 1993. Laminin-binding protein 120 from brain is closely related to the dystrophin-associated glycoprotein, dystroglycan, and binds with high affinity to the major heparin binding domain of laminin. J. Biol. Chem. 268:14972-80
14. Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, et al. 2001. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am. J. Hum. Genet. 69:1198-209
15. Kondo-Iida E, Kobayashi K, Watanabe M, Sasaki J, Kumagai T, et al. 1999. Novel mutations and genotype-phenotype relationships in 107 families with Fukuyama-type congenital muscular dystrophy (FCMD). Hum. Mol. Genet. 8:2303-9
16. Kirschner J, Bonnemann CG. 2004. The congenital and limb-girdle muscular dystrophies: sharpening the focus, blurring the boundaries. Arch. Neurol. 61:189-99
17. Muntoni F. 2004. Journey into muscular dystrophies caused by abnormal glycosylation. Acta Myol. 23:79-84
18. Haliloglu G, Topaloglu H. 2004. Glycosylation defects in muscular dystrophies. Curr. Opin. Neurol. 17:521-27
19. Torelli S, Brown SC, Brockington M, Dolatshad NF, Jimenez C, et al. 2005. Sub-cellular localisation of fukutin related protein in different cell lines and in the muscle of patients with MDC1C and LGMD2I. Neuromuscul. Disord. 15:836-43
20. Esapa CT, McIlhinney RA, Blake DJ. 2005. Fukutin-related protein mutations that cause congenital muscular dystrophy result in ER-retention of the mutant protein in cultured cells. Hum. Mol. Genet. 14:295-305
21. Grewal PK, McLaughlan JM, Moore CJ, Browning CA, Hewitt JE. 2005. Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies. Glycobiology 15:912-23
22. Matsumoto H, Noguchi S, Sugie K, Ogawa M, Murayama K, et al. 2004. Subcellular localization of fukutin and fukutin-related protein in muscle cells. J. Biochem. 135:709-12
23. Guicheney P, Vignier N, Helbling-Leclerc A, Nissinen M, Zhang X, et al. 1997. Genetics of laminin alpha 2 chain (or merosin) deficient congenital muscular dystrophy: from identification of mutations to prenatal diagnosis. Neuromuscul. Disord. 7:180-86
24. Pegoraro E, Marks H, Garcia CA, Crawford T, Mancias P, et al. 1998. Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. Neurology 51:101-10
25. Miller RG, Hoffman EP. 1994. Molecular diagnosis and modern management of Duchenne muscular dystrophy. Neurol. Clin. 12:699-725
26. Chaturvedi LS, Mukherjee M, Srivastava S, Mittal RD, Mittal B. 2001. Point mutation and polymorphism in Duchenne/Becker muscular dystrophy (D/BMD) patients. Exp. Mol. Med. 33:251-56
27. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. 1989. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244:1578-80
28. Howard MT, Anderson CB, Fass U, Khatri S, Gesteland RF, et al. 2004. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann. Neurol. 55:422-26
29. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. 1999. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 104:375-81
30. Hoogerwaard EM, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, et al. 1999. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet 353:2116-19
31. Koenig M, Kunkel LM. 1990. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J. Biol. Chem. 265:4560-66
32. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. 1992. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 355:696-702
33. Rybakova IN, Patel JR, Ervasti JM. 2000. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J. Cell Biol. 150:1209-14
34. Matsuda R, Nishikawa A, Tanaka H. 1995. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: evidence of apoptosis in dystrophin-deficient muscle. J. Biochem. 118:959-64
35. Straub V, Rafael JA, Chamberlain JS, Campbell KP. 1997. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell Biol. 139:375-85
36. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, et al. 2004. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10:828-34
37. Alderton JM, Steinhardt RA. 2000. How calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. Trends Cardiovasc. Med. 10:268-72
38. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. 1990. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345:315-19
39. Yoshida M, Ozawa E. 1990. Glycoprotein complex anchoring dystrophin to sarcolemma. J. Biochem. 108:748-52
40. Lapidos KA, Kakkar R, McNally EM. 2004. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ. Res. 94:1023-31
41. Lovering RM, Porter NC, Bloch RJ. 2005. The muscular dystrophies: from genes to therapies. Phys. Ther. 85:1372-88
42. Loufrani L, Levy BI, Henrion D. 2002. Defect in microvascular adaptation to chronic changes in blood flow in mice lacking the gene encoding for dystrophin. Circ. Res. 91:1183-89
43. Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, et al. 2000. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 97:13818-23
44. Thomas GD, Shaul PW, Yuhanna IS, Froehner SC, Adams ME. 2003. Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal Nitric oxide synthase. Circ. Res. 92:554-60
45. Ozawa E, Mizuno Y, Hagiwara Y, Sasaoka T, Yoshida M. 2005. Molecular and cell biology of the sarcoglycan complex. Muse. Nerv. 32:563-76
46. Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, et al. 2001. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat. Genet. 29:66-69
47. Wheeler MT, Zarnegar S, McNally EM. 2002. Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum. Mol. Genet. 11:2147-54
48. Bueno MR, Moreira ES, Vainzof M, Chamberlain J, Marie SK, et al. 1995. A common missense mutation in the adhalin gene in three unrelated Brazilian families with a relatively mild form of autosomal recessive limb-girdle muscular dystrophy. Hum. Mol. Genet. 4:1163-67
49. McNally EM, Passos-Bueno MR, Bonnemann CG, Vainzof M, de Sa Moreira E, et al. 1996. Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am. J. Hum. Genet. 59:1040-47
50. Heydemann A, Huber JM, Demonbreun A, Hadhazy M, McNally EM. 2005. Genetic-background influences muscular dystrophy. Neuromuscul. Disord. 15:601-9
51. Vainzof M, Passos-Bueno MR, Canovas M, Moreira ES, Pavanello RC, et al. 1996. The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. Hum. Mol. Genet. 5:1963-69
52. Hack AA, Lam MY, Cordier L, Shoturma DI, Ly CT, et al. 2000. Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J. Cell Sci. 113(Pt 14):2535-44
53. Straub V, Ettinger AJ, Durbeej M, Venzke DP, Cutshall S, et al. 1999. ε-sarcoglycan replaces α-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex. J. Biol. Chem. 274:27989-96
54. Coral-Vazquez R, Cohn RD, Moore SA, Hill JA, Weiss RM, et al. 1999. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98:465-74
55. Wheeler MT, Allikian MJ, Heydemann A, Hadhazy M, Zarnegar S, McNally EM. 2004. Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J. Clin. Invest. 113:668-75
56. Anderson LV, Davison K, Moss JA, Young C, Cullen MJ, et al. 1999. Dysferlin is a plasma membrane protein and is expressed early in human development. Hum. Mol. Genet. 8:855-61
57. Achanzar WE, Ward S. 1997. A nematode gene required for sperm vesicle fusion. J. Cell Sci. 110:1073-81
58. Ward S, Argon Y, Nelson GA. 1981. Sperm morphogenesis in wild-type and fertilization-defective mutants of Caenorhabditis elegans. J. Cell Biol. 91:26-44
59. Piccolo F, Moore SA, Ford GC, Campbell KP. 2000. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb-girdle muscular dystrophies. Ann. Neurol. 48:902-12
60. Selcen D, Stilling G, Engel AG. 2001. The earliest pathologic alterations in dysferlinopathy. Neurology 56:1472-81
61. Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, et al. 2003. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423:168-72
62. Cenacchi G, Fanin M, De Giorgi LB, Angelini C. 2005. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J. Clin. Pathol. 58:190-95
63. Doherty KR, McNally EM. 2003. Repairing the tears: dysferlin in muscle membrane repair. Trends Mol. Med. 9:327-30
64. Fernandez-Chacon R, Konigstorfer A, Gerber SH, Garcia J, Matos MF, et al. 2001. Synaptotagmin I functions as a calcium regulator of release probability. Nature 410:41-49
65. Davis DB, Doherty KR, Delmonte AJ, McNally EM. 2002. Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J. Biol. Chem. 277:22883-88
66. Davis DB, Delmonte AJ, Ly CT, McNally EM. 2000. Myoferlin, a candidate gene and potential modifier of muscular dystrophy. Hum. Mol. Genet. 9:217-26
67. Doherty KR, Cave A, Davis DB, Delmonte AJ, Posey A, et al. 2005. Normal myoblast fusion requires myoferlin. Development 132:5565-75
68. McNally EM, Ly CT, Rosenmann H, Mitrani Rosenbaum S, Jiang W, et al. 2000. Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. Am. J. Med. Genet. 91:305-12
69. Gallardo E, Rojas-Garcia R, de Luna N, Pou A, Brown RHJ, Illa I. 2001. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57:2136-38
70. Hoffman EP, Rao D, Pachman LM. 2002. Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. Rheum. Dis. Clin. North Am. 28:743-57
71. Weiler T, Bashir R, Anderson LV, Davison K, Moss JA, et al. 1999. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum. Mol. Genet. 8:871-77
72. Zatz M, Starling A. 2005. Calpains and disease. N. Engl. J. Med. 352:2413-23
73. Guyon JR, Kudryashova E, Potts A, Dalkilic I, Brosius MA, et al. 2003. Calpain 3 cleaves filamin C and regulates its ability to interact with gamma- and delta-sarcoglycans. Musc. Nerv. 28:472-83
74. Sorimachi H, Kinbara K, Kimura S, Takahashi M, Ishiura S, et al. 1995. Muscle-specific calpain, p94, responsible for limb girdle muscular dystrophy type 2A, associates with connectin through IS2, a p94-specific sequence. J. Biol. Chem. 270:31158-62
75. Garvey SM, Rajan C, Lerner AP, Frankel WN, Cox GA. 2002. The muscular dystrophy with myositis (mdm) mouse mutation disrupts a skeletal muscle-specific domain of titin. Genomics 79:146-49
76. Woodman SE, Sotgia F, Galbiati F, Minetti C, Lisanti MP. 2004. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology 62:538-43
77. Walter MC, Braun C, Vorgerd M, Poppe M, Thirion C, et al. 2003. Variable reduction of caveolin-3 in patients with LGMD2B/MM. J. Neurol. 250:1431-38
78. Kudryashova E, Kudryashov D, Kramerova I, Spencer MJ. 2005. Trim32 is a ubiquitin ligase mutated in limb girdle muscular dystrophy type 2H that binds to skeletal muscle myosin and ubiquitinates actin. J. Mol. Biol. 354:413-24
79. Hauser MA, Horrigan SK, Salmikangas P, Torian UM, Viles KD, et al. 2000. Myotilin is mutated in limb girdle muscular dystrophy 1A. Hum. Mol. Genet. 9:2141-47
80. Pyle WG, Solaro RJ. 2004. At the crossroads of myocardial signaling: the role of Z-discs in intracellular signaling and cardiac function. Circ. Res. 94:296-305
81. Wallgren-Pettersson C. 2002. Nemaline and myotubular myopathies. Semin. Pediatr. Neurol. 9:132-44
82. Segura-Totten M, Wilson KL. 2004. BAF: roles in chromatin, nuclear structure and retrovirus integration. Trends Cell Biol. 14:261-66
83. Ostlund C, Worman HJ. 2003. Nuclear envelope proteins and neuromuscular diseases. Musc. Nerv. 27:393-406
84. Helbling-Leclerc A, Bonne G, Schwartz K. 2002. Emery-Dreifuss muscular dystrophy. Eur. J. Hum. Genet. 10:157-61
85. Smith ED, Kudlow BA, Frock RL, Kennedy BK. 2005. A-type nuclear lamins, progerias and other degenerative disorders. Mech. Ageing Dev. 126:447-60
86. Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, et al. 2004. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J. Clin. Invest. 113:370-78
87. Lammerding J, Hsiao J, Schulze PC, Kozlov S, Stewart CL, Lee RT. 2005. Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J. Cell Biol. 170:781-91
88. Bakay M, Wang Z, Melcon G, Schiltz L, Xuan J, et al. 2006. Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain 129(4):996-1013
89. Melcon G, Kozlov S, Cutler DA, Sullivan T, Hernandez L, et al. 2006. Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. Hum. Mol. Genet. 15:637-51
90. Frock RL, Kudlow BA, Evans AM, Jameson SA, Hauschka SD, Kennedy BK. 2006. Lamin A/C and emerin are critical for skeletal muscle satellite cell differentiation. Genes Dev. 20:486-500
91. Machuca-Tzili L, Brook D, Hilton-Jones D. 2005. Clinical and molecular aspects of the myotonic dystrophies: a review. Musc. Nerv. 32:1-18
92. Mankodi A, Logigian E, Callahan L, McClain C, White R, et al. 2000. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 289:1769-73
93. Miller JW, Urbinati CR, Teng-Umnuay P, Stenberg MG, Byrne BJ, et al. 2000. Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J. 19:4439-48
94. Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, et al. 2001. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum. Mol. Genet. 10:2165-70
95. Ho TH, Charlet BN, Poulos MG, Singh G, Swanson MS, Cooper TA. 2004. Muscleblind proteins regulate alternative splicing. EMBO J. 23:3103-12
96. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, et al. 2003. A muscleblind knockout model for myotonic dystrophy. Science 302:1978-80
97. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, et al. 2001. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293:864-67
98. Ranum LP, Day JW. 2002. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2. Curr. Neurol. Neurosci. Rep. 2:465-70
99. Schoser BG, Ricker K, Schneider-Gold C, Hengstenberg C, Durre J, et al. 2004. Sudden cardiac death in myotonic dystrophy type 2. Neurology 63:2402-4
100. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, et al. 2003. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60:657-64
101. Tupler R, Gabellini D. 2004. Molecular basis of facioscapulohumeral muscular dystrophy. Cell Mol. Life Sci. 61:557-66
102. Tawil R. 2004. Facioscapulohumeral muscular dystrophy. Curr. Neurol. Neurosci. Rep. 4:51-54
103. Gabellini D, D'Antona G, Moggio M, Prelle A, Zecca C, et al. 2006. Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1. Nature 439:973-77
104. van Deutekom JC, Lemmers RJ, Grewal PK, van Geel M, Romberg S, et al. 1996. Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35. Hum. Mol. Genet. 5:581-90
105. Masny PS, Bengtsson U, Chung SA, Martin JH, van Engelen B, et al. 2004. Localization of 4q35.2 to the nuclear periphery: Is FSHD a nuclear envelope disease? Hum. Mol. Genet. 13:1857-71
106. Lee SJ, McPherron AC. 1999. Myostatin and the control of skeletal muscle mass. Curr. Opin. Genet. Dev. 9:604-7
107. Lee SJ, McPherron AC. 2001. Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. USA 98:9306-11
108. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, et al. 2003. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem. Biophys. Res. Commun. 300:965-71
109. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, et al. 2002. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420:418-21
110. Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS. 2005. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J. 19:543-49
111. Musaro A, McCullagh KJ, Naya FJ, Olson EN, Rosenthal N. 1999. IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400:581-85
112. Barton ER, Morris L, Musaro A, Rosenthal N, Sweeney HL. 2002. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J. Cell Biol. 157:137-48
113. Yang SY, Goldspink G. 2002. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 522:156-60